Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol TIVA for Breast Surgery
NCT05375747Withdrawn
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of remimazolam in breast cancer (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Hypotension incidence. Planned start Jun 2022; status: withdrawn.
02
Drugs
remimazolam
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05375747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375747.